11 May 06
A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
10 May 06
This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited
25 Apr 06
Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
07 Apr 06
COPD is a disease that will grow in importance in the future and it will have a major impact on society, particular amongst those that smoke. At the moment, although new treatments are being developed for COPD the pharmaceutical market remains undeveloped. There will be a high demand for effective medicines and so COPD should be an area of interest for pharmaceutical companies who specialise in the respiratory therapeutic field.
Dr Faiz Kermani
07 Apr 06
Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. The government policies that are being developed have important implications for pharmaceutical companies looking to expand in this emerging pharmaceutical region.
Dr Faiz Kermani
06 Apr 06
SMiās Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials.
Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the u
03 Apr 06
Corning Life Sciences today announced the addition of digital displays and enhanced features to its hot plates, stirrers and stirring hot plates. The new digital display features include: a digital temperature display adjustable in 5 degree increments and set temperature indicator; optimum digital stir speed display indicator; and an external temperature controller for precision accuracy āinside the beaker.ā
Corning Life Sciences
03 Apr 06
Corning Life Sciences today announced several new products coated with the Ultra-Low Attachment surface including the 25 and 75 cm2 flasks and CELLSTACKĀ® Culture Chambers which are well-suited for many cell culture applications including stem cell, cancer, and immune system research, and enable customers to increase the scale of cell culture, improve yields, and reduce contamination risks
Corning Life Sciences
30 Mar 06
Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
29 Mar 06
Deployable medicine involves the complete employment of military health professionals. The nature of the deployment can vary from conventional āwarfightingā campaigns to humanitarian relief operations. The methods for employing highly skilled military professionals within the area or operations and the level of care they provide are crucial to the success of the mission
29 Mar 06
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
28 Mar 06
Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
22 Mar 06
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.Ā The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.Ā Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
21 Mar 06
If Sales Force Effectiveness is high on your agenda in the current climate, then donāt miss Pharma IQās Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
01 Mar 06
Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
28 Feb 06
ICONās core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
24 Feb 06
Abbott recently had the largest gain in reputation of any company in its industry
when Fortune magazine ranked it number three in the magazineās list of the
most admired companies in the United States ā Fortuneās highest ranking for
Abbott since 1989. How was this achieved and what factors led up to it?
24 Feb 06
In an increasingly complex world, with significant changes taking place on a social,
commercial and economic basis almost weekly, corporate social responsibility is a
priority for Abbott as it engages its stakeholders, advances its core objectives and
exercises its influence ā making productive contribution to the societies and
communities it operates in.
21 Feb 06
Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
20 Feb 06
Although COPD is a devastating disease affecting an estimated one in 10 people aged 45 and older, up to 80% of sufferers are unaware they have it. Furthermore, even for patients who do receive treatment, current therapies do not stop the disease's progression. Until better treatments are available, then, efforts must focus on improving smoking cessation therapies and increasing awareness of COPD.
10 Feb 06
The approval of Novartisā Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartisā second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
09 Feb 06
The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitorās report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Obesity is an active area of R&D and numerous novel molecular targets are currently being evaluated. One target, ghrelin was the subject of a major target discovery report from LeadDiscovery published in 2003 Ghrelin: Pharmaceutical & Ther
03 Feb 06
The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi